GALD (GALD) News
Follow GALD (GALD) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 18 public stories across 8 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Galderma Receives China Approval for Relfydess
China’s NMPA approved Relfydess (relabotulinumtoxinA) to treat moderate-to-severe frown lines in adults.
REGULATION | Oct 23, 2026, 05:00 AM UTC
M
Galderma Raises Revenue Outlook as Quarterly Sales Beat Consensus
Vontobel says Galderma lifted its revenue outlook for the year more than expected and quarterly sales beat consensus estimates. Investor concerns about skin medication Nemluvio's growth did not materialize, the analyst s
EARNINGS | Oct 22, 2026, 02:12 PM UTC
M
Galderma Q3 Sales Climb; Raises FY26 Sales Growth Outlook
Galderma reported third-quarter sales of $1.63 billion and raised its sales growth outlook while confirming its FY26 core EBITDA margin view.
EARNINGS | Oct 22, 2026, 07:42 AM UTC
M
Galderma Raises Full-Year Net Sales Guidance After Nine-Month Results
Galderma reported net sales for the first nine months of 2026, up 25.1% year on year on a constant-currency basis.
EQUITY | Oct 22, 2026, 07:32 AM UTC
M
Galderma Raises Full-Year Sales Guidance for Second Time in Two Quarters
Galderma raised its full-year sales guidance after robust sales growth in the first nine months, particularly in its therapeutic dermatology division.
EARNINGS | Oct 22, 2026, 06:20 AM UTC
M
Galderma Nine-Month Sales Rise on Higher Volumes; Outlook Lifted
EARNINGS | Oct 22, 2026, 05:09 AM UTC
M
Galderma Reports Nine-Month Net Sales of 4.765 B USD, Raises Guidance
Galderma reported nine-month net sales of 4.765 B USD, up 25.1% year on year at constant currency, and raised its full-year net sales guidance.
EARNINGS | Oct 22, 2026, 05:06 AM UTC
M
Galderma Reports 9M Net Sales of $4.765 Billion
EQUITY | Oct 22, 2026, 05:05 AM UTC
M
Galderma Agrees to Buy ZO Skin Health for $1.5 Billion
Galderma Group agreed to buy ZO Skin Health from Blackstone, the Obagi family and other shareholders for $1.5 billion, including debt, to expand its premium skincare portfolio.
MNA | Oct 14, 2026, 07:33 AM UTC
M
Galderma to Buy ZO Skin Health for $1.5B
The acquisition is expected to be EPS-neutral in its first year.
MNA | Oct 14, 2026, 07:01 AM UTC
M
Galderma Agrees to Acquire ZO Skin Health
Galderma signed an agreement to acquire ZO Skin Health, strengthening its physician-dispensed skincare offering.
EQUITY | Oct 14, 2026, 05:23 AM UTC
M
Galderma Deal Valued at $1.5 Billion
MNA | Oct 14, 2026, 05:04 AM UTC
M
Galderma Agrees to Buy ZO Skin Health for About $1.5 Billion
Galderma has agreed to acquire ZO Skin Health for around $1.5 billion, according to two people familiar with the matter. The deal could be announced in the coming days.
MNA | Oct 13, 2026, 11:13 PM UTC
L
Galderma's Nemluvio Shows Sustained Three-Year Benefits In Atopic Dermatitis
WASHINGTON (dpa-AFX) - Galderma (GALD) reported new three-year data from the ARCADIA long-term extension study showing that Nemluvio (nemolizumab) was associated with sustained improvements in skin lesions, itch, sleep d
NEWS | Sep 30, 2026, 06:01 AM UTC
L
Galderma Group Says New Data Show Sustained Improvements With Nemluvio (Nemolizumab) For Up To Three Years In Patients With Moderate-To-Severe Atopic Dermatitis
GALDERMA GROUP AG BX:GALD
NEWS | Sep 30, 2026, 05:04 AM UTC
H
EADV 2026: Galderma to Unveil New Data Advancing Understanding of Skin Diseases, Skin Longevity, and Real-world Patient Experiences
Galderma (SIX: GALD), the pure-play dermatology category leader, will present 19 abstracts and deliver a broad scientific education program at the 2026 European Academy of Dermatology and Venereology (EADV) Congress. Thr
GEOPOLITICS | Sep 23, 2026, 05:00 AM UTC
M
Galderma: Restylane Volyme study meets primary endpoint
EQUITY | Sep 16, 2026, 05:03 AM UTC
L
From Ozempic Face to K-Beauty Factories: The Next Beauty Bet
FROM OZEMPIC FACE TO K-BEAUTY FACTORIES: THE NEXT BEAUTY BETFrom gaunt "Ozempic face" to K-beauty factories quietly powering global skincare, analysts at BCA Research say a multibillion-dollar "beauty economy" is emergin
NEWS | Sep 15, 2026, 03:34 PM UTC